Pembrolizumab
Treatment for Stomach Cancer
Typical Dosage: 200 mg IV every 3 weeks or 400 mg IV every 6 weeks
Effectiveness
70%
Safety Score
40%
Clinical Trials
161
Participants
15K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
40
DangerousModerateSafe
Treatment Details
Dosage Range
200 mg IV every 3 weeks or 400 mg IV every 6 weeks
Time to Effect
4-12 weeks
Treatment Duration
Up to 2 years or until progression/unacceptable toxicity
Evidence Quality
HIGHNumber Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
20(Treat 20 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$150,000
Monitoring:$10,000
Side Effect Mgmt:$5,000
Total Annual:$165,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$400,000/QALY
QALYs Gained
0.5
Outcome-Based Costs
Cost per Responder
$1,100,000
Cost per Remission
$8,250,000
Comparison vs Chemotherapy (e.g., Paclitaxel)
Cost Difference
+$100,000/year
More expensive
QALY Difference
+0.20 QALYs
Better outcomes
Dominance
No dominance
Active Clinical Trials
5 active trials recruiting for Pembrolizumab in Stomach Cancer
A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
NCT07315750NOT YET RECRUITINGPHASE3
555 participants
INTERVENTIONAL
Beijing, China
Started: Jan 1, 2026
Pembrolizumab + Capecitabine／Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive
NCT04249739ACTIVE NOT RECRUITINGPHASE2
93 participants
INTERVENTIONAL
Seoul, South Korea
Started: Sep 29, 2020
Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma
NCT03488667ACTIVE NOT RECRUITINGPHASE2
40 participants
INTERVENTIONAL
Westwood, United States
Started: Jun 27, 2018
A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
NCT06116136ACTIVE NOT RECRUITINGPHASE1, PHASE2
38 participants
INTERVENTIONAL
Ocala, United States +48 more
Started: Aug 31, 2024
Exploratory Single-arm, Single-center Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer With Combination of Palizumab and SOX Regimen
NCT06036745RECRUITINGPHASE2
20 participants
INTERVENTIONAL
Shanghai, China
Started: Jul 1, 2022
Completed Clinical Trials
10 completed trials for Pembrolizumab in Stomach Cancer
Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
NCT03675737COMPLETEDPHASE3
1.58K participants
INTERVENTIONAL
Los Angeles, United States +214 more
Started: Nov 8, 2018
Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)
NCT03064490COMPLETEDPHASE2
35 participants
INTERVENTIONAL
Durham, United States
Started: Oct 17, 2017
Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors
NCT03043664COMPLETEDPHASE1, PHASE2
22 participants
INTERVENTIONAL
Durham, United States +1 more
Started: Jul 1, 2017
Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
NCT03615326COMPLETEDPHASE3
738 participants
INTERVENTIONAL
Los Angeles, United States +191 more
Started: Oct 5, 2018
Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma
NCT04798781COMPLETEDPHASE2
16 participants
INTERVENTIONAL
Beverly Hills, United States +2 more
Started: Jul 28, 2021
FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric Cancer
NCT04768686COMPLETEDPHASE2
20 participants
INTERVENTIONAL
Anyang-si, South Korea +9 more
Started: May 18, 2021
A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors
NCT02563548COMPLETEDPHASE1
56 participants
INTERVENTIONAL
Birmingham, United States +27 more
Started: Oct 22, 2015
Lenvatinib and Pembrolizumab Simultaneous Combination Study
NCT03609359COMPLETEDPHASE2
29 participants
INTERVENTIONAL
Kashiwa, Japan
Started: Oct 3, 2018
Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659)
NCT03382600COMPLETEDPHASE2
100 participants
INTERVENTIONAL
Kashiwa, Japan +24 more
Started: Mar 26, 2018
An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients
NCT04099641COMPLETEDPHASE2
80 participants
INTERVENTIONAL
New Haven, United States +20 more
Started: Sep 11, 2019
Showing 20 of 165 total trials